These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38496485)

  • 1. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
    Kang MK; Song J; Loomba R; Park S; Tak W; Kweon Y; Lee Y; Park JG
    Res Sq; 2024 Mar; ():. PubMed ID: 38496485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.
    Kang MK; Song JE; Loomba R; Park SY; Tak WY; Kweon YO; Lee YR; Park JG
    Sci Rep; 2024 Oct; 14(1):22917. PubMed ID: 39358447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
    Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
    Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Kang MK; Song JE; Kweon YO; Tak WY; Park SY; Lee YR; Park JG
    Diagnostics (Basel); 2024 Oct; 14(20):. PubMed ID: 39451628
    [No Abstract]   [Full Text] [Related]  

  • 5. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAFLD predicts cardiovascular disease risk better than MASLD.
    Pan Z; Shiha G; Esmat G; Méndez-Sánchez N; Eslam M
    Liver Int; 2024 Jul; 44(7):1567-1574. PubMed ID: 38641962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease.
    Kang MK; Lee YR; Jang SY; Tak WY; Kweon YO; Song JE; Loomba R; Park SY; Park JG
    Hepatol Int; 2023 Jun; 17(3):626-635. PubMed ID: 37069419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: A meta-analysis.
    De Filippo O; Di Pietro G; Nebiolo M; Ribaldone DG; Gatti M; Bruno F; Gallone G; Armandi A; Birtolo LI; Zullino V; Mennini G; Corradini SG; Mancone M; Bugianesi E; Iannaccone M; De Ferrari GM; D'Ascenzo F
    Eur J Clin Invest; 2024 Sep; 54(9):e14188. PubMed ID: 38396359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of overweight/obesity and overweight/obesity-related metabolic dysfunction-associated steatotic liver disease in young adults with coronary artery calcification later in life.
    Wang JJ; Zheng Z; Zhang Y
    Diabetes Obes Metab; 2024 Sep; 26(9):3860-3867. PubMed ID: 38934214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MAFLD identifies patients with significant hepatic fibrosis better than MASLD.
    Pan Z; Al-Busafi SA; Abdulla M; Fouad Y; Sebastiani G; Eslam M
    Hepatol Int; 2024 Jun; 18(3):964-972. PubMed ID: 38717690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.
    Zou H; Ma X; Pan W; Xie Y
    Front Nutr; 2024; 11():1411802. PubMed ID: 39040926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Sep; 49(9):3036-3044. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features and mortality outcomes of patients with MASLD only compared to those with MAFLD and MASLD.
    Jiang M; Pan Z; George J; Eslam M
    Hepatol Int; 2024 Dec; 18(6):1731-1739. PubMed ID: 39196505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease.
    Pan Z; Derbala M; AlNaamani K; Ghazinian H; Fan JG; Eslam M
    Ann Hepatol; 2024; 29(5):101512. PubMed ID: 38710473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of MAFLD and MASLD with all-cause and cause-specific dementia: a prospective cohort study.
    Bao X; Kang L; Yin S; Engström G; Wang L; Xu W; Xu B; Zhang X; Zhang X
    Alzheimers Res Ther; 2024 Jun; 16(1):136. PubMed ID: 38926784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.